HomeGLP-1 Medicines Explained
GLP-1 Medicines Explained
Plain-language pages on each GLP-1 medicine: what it is, what it is approved for, doses and where to find its price. One page per medicine, including the ones still in trials.
All countries
Tirzepatide (Zepbound, Mounjaro) for Weight LossTirzepatide is a once-weekly injection sold as Zepbound and Mounjaro, with doses from 2.5 mg to 15 mg. There i
GLP-1 Drugs ExplainedGLP-1 drugs include semaglutide, tirzepatide and liraglutide injections and three daily pills. See each medici
Mounjaro (Tirzepatide)Mounjaro is a once-weekly tirzepatide injection approved for type 2 diabetes and, in the UK, EU and India, wei
Ozempic (Semaglutide)Ozempic is a once-weekly semaglutide injection for type 2 diabetes, 0.25 mg to 2 mg, not approved for weight l
Wegovy (Semaglutide) for Weight LossWegovy is Novo Nordisk's semaglutide for weight loss: a weekly injection (0.25 mg start, 2.4 mg usual, 7.2 mg
Semaglutide for Weight LossSemaglutide is the ingredient in Wegovy, Ozempic and Rybelsus. Wegovy is the weight-loss brand, as a weekly in
Wegovy PillThe Wegovy pill is once-daily semaglutide: 1.5 mg start, 25 mg maintenance from day 91. Doses, how to take it,
Foundayo (Orforglipron)Foundayo (orforglipron) is Lilly's once-daily GLP-1 weight loss pill. FDA approved April 1, 2026, UK August 10
Rybelsus (Semaglutide Tablets)Rybelsus is a once-daily semaglutide tablet for type 2 diabetes, not approved for weight loss. Tablet strength
Liraglutide (Saxenda, Victoza)Liraglutide is a once-daily injection. Saxenda is approved for weight loss and goes up to 3 mg; Victoza is for
Eloralintide and AmycretinEloralintide (Lilly) and amycretin (Novo Nordisk) are amylin weight loss drugs still in trials. Eloralintide c
Survodutide: Trial Results and Expected Approval TimelineSurvodutide is not approved anywhere as of November 20, 2026. In a 76-week phase 3 trial, weight fell about 12
CagriSema (Novo Nordisk)CagriSema is Novo Nordisk's once-weekly weight loss injection, not yet approved. FDA decision expected in Q4 2